AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00290498
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1
Trial: NCT00290498
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
Trial: NCT00290498
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
Trial: NCT00329615
Drug: Insulatard, flexpen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00575874
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablets or capsule once daily for 12 weeks
Trial: NCT03381417
Drug: pegcyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Trial: NCT03381417
Drug: Neulastim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Trial: NCT01591473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; 3 doses; nasal administration every 28 days
Trial: NCT00517569
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
Trial: NCT01856621
Drug: Seretide Diskus and charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT01856621
Drug: SF Easyhaler and charcoal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT04584710
Drug: RTB101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
Trial: NCT00908037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for comparison
Trial: NCT04584710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral matching placebo once daily for 2 weeks
Trial: NCT01716104
Drug: Afalaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and Efficacy
Trial: NCT01716104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and Efficacy
Trial: NCT01979939
Drug: DCV/ASV/BMS-791325
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242357
Drug: Micardis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242357
Drug: Micardis® Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02357420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given subcutaneously for 12 weeks.
Trial: NCT02415309
Drug: 2 mg Melatonin
RxNorm normalized name: melatonin 2 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 patients will randomly receive 2 mg melatonin
Trial: NCT02415309
Drug: 10mg Melatonin
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 patients will randomly receive 10 mg melatonin
Trial: NCT00758641
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: kenacort 40 mg/ml triamcinolon acetonide
Trial: NCT02460341
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill
Trial: NCT02739516
Drug: FSH co-trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
Trial: NCT02365571
Drug: LY3154207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02365571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03329378
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 IV day 1
Trial: NCT03329378
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m2 IV day 1
Trial: NCT00474240
Drug: AEGR-733 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00474240
Drug: AEGR-733 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00474240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01418209
Drug: Low-dose 17-ß-estradiol with progesterone taper
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
Trial: NCT01418209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is an inactive pill that looks like the active medication.
Trial: NCT02310997
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00663845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01380704
Drug: ABT-436
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD Days 1-7
Trial: NCT01380704
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD Days 1-7
Trial: NCT01435837
Drug: C3(200mg of caffeine; 1 L of water)
RxNorm normalized name: caffeine 200 MG [Revive brand of caffeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
Trial: NCT01435837
Drug: Placebo (no caffeine, no water).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ingestion of caffeine; no ingestion of water between pretest and posttest.
Trial: NCT01583660
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg, PO.Bid, last from admission to hospital to one week after operation.
Trial: NCT01583660
Drug: Acetaminophen oxycodone
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
Trial: NCT00697281
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily for 8 days~Dose level 1
Trial: NCT00697281
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily for 8 days~Dose level 2
Trial: NCT00697281
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily for 8 days~Dose level 3
Trial: NCT00697281
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily for 8 days~Dose level 4
Trial: NCT00697281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily for 8 days~Dose level 5
Trial: NCT00903331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo, once daily
Trial: NCT03057470
Drug: 50% bolus insulin correction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
Trial: NCT03057470
Drug: 100% bolus insulin correction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
Trial: NCT03057470
Drug: 150% bolus insulin correction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
Trial: NCT02754960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
Trial: NCT01409369
Drug: RO4995819
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT00257660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 units
Trial: NCT00211952
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00094107
Drug: Axitinib [AG-013736]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
Trial: NCT01786252
Drug: Placebo Comparator (for hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50ul of IVF medium (Global-trademark) to mimic hCG infusion
Trial: NCT00637039
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
Trial: NCT01749891
Drug: ALG 1001
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
Trial: NCT00647660
Drug: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80/5mg, single dose fasting
Trial: NCT00647660
Drug: Corzide® Tablets 80 mg/5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80/5mg, single dose fasting
Trial: NCT02409862
Drug: Placebo Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
Trial: NCT00446186
Drug: Comparator: placebo / Duration of Treatment: 2 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01167868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01399268
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
Trial: NCT02335060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
Trial: NCT02335060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar pill given orally with no N-acetylcysteine.
Trial: NCT03757754
Drug: HPPH 2.5 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Trial: NCT03757754
Drug: HPPH 3 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Trial: NCT03757754
Drug: HPPH 3.5 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Trial: NCT03757754
Drug: HPPH 4 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Trial: NCT03757754
Drug: HPPH 5 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Trial: NCT03757754
Drug: HPPH 6 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
Trial: NCT01060267
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
Trial: NCT01060267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
Trial: NCT04402541
Drug: CB-5339
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg and 75mg capsules
Trial: NCT00558272
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose
Trial: NCT00558272
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02472236
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200µg,injected subcutaneously,once a week.
Trial: NCT01836393
Drug: Plavina cream
RxNorm normalized name: NIACINAMIDE 2 g in 100 g / ADENOSINE 0.04 g in 100 g TOPICAL CREAM [TAEYANGSOO Plavital RxCream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
Trial: NCT01342562
Drug: spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
Trial: NCT01342562
Drug: spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
Trial: NCT01147497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
Trial: NCT00245271
Drug: OMS103HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
Trial: NCT00245271
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
Trial: NCT02543931
Drug: Meriva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
Trial: NCT02543931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules containing inert ingredients
Trial: NCT00648531
Drug: Colazal® Capsules 750 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x750mg, single dose fasting
Trial: NCT02014584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride matching placebo will be supplied as capsules to be administered orally.
Trial: NCT04122443
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650mg
Trial: NCT00006455
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006455
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006455
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006455
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006455
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02161419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
Trial: NCT00552604
Drug: standardized cannabis extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
Trial: NCT00552604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, twice daily
Trial: NCT03693781
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding tablets for 30 weeks
Trial: NCT00527332
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
Trial: NCT00527332
Drug: Rocuronbromid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
Trial: NCT00302757
Drug: Radioimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02160145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Trial: NCT02012049
Drug: Risperdal OD Tab. 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Risperdal OD 2 mg administered orally.
Trial: NCT02012049
Drug: Risperdal Quicklet Tab. 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Risperdal Quicklet Tab. 2mg administered orally.
Trial: NCT03667690
Drug: intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT03667690
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose
Trial: NCT01307462
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01340183
Drug: AZD5099
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Dose
Trial: NCT01340183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Dose
Trial: NCT02915744
Drug: NKTR-102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into detrusor on Day 1
Trial: NCT04584242
Drug: suganon tab 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST
Trial: NCT00355264
Drug: Phenoptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
Trial: NCT01480739
Drug: 100 mg (50 mg x 2) AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for 7 days
Trial: NCT01480739
Drug: 100 mg Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily for 7 days
Trial: NCT02807870
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill during 8 weeks.
Trial: NCT00959127
Drug: ARRY-438162 (MEK162), MEK inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.